198 related articles for article (PubMed ID: 18991635)
1. Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosis.
Hegymegi-Barakonyi B; Székely R; Varga Z; Kiss R; Borbély G; Németh G; Bánhegyi P; Pató J; Greff Z; Horváth Z; Mészáros G; Marosfalvi J; Erōs D; Szántai-Kis C; Breza N; Garavaglia S; Perozzi S; Rizzi M; Hafenbradl D; Ko M; Av-Gay Y; Klebl BM; Orfi L; Kéri G
Curr Med Chem; 2008; 15(26):2760-70. PubMed ID: 18991635
[TBL] [Abstract][Full Text] [Related]
2. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling.
Székely R; Wáczek F; Szabadkai I; Németh G; Hegymegi-Barakonyi B; Eros D; Szokol B; Pató J; Hafenbradl D; Satchell J; Saint-Joanis B; Cole ST; Orfi L; Klebl BM; Kéri G
Immunol Lett; 2008 Mar; 116(2):225-31. PubMed ID: 18258308
[TBL] [Abstract][Full Text] [Related]
3. Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents.
Lougheed KE; Osborne SA; Saxty B; Whalley D; Chapman T; Bouloc N; Chugh J; Nott TJ; Patel D; Spivey VL; Kettleborough CA; Bryans JS; Taylor DL; Smerdon SJ; Buxton RS
Tuberculosis (Edinb); 2011 Jul; 91(4):277-86. PubMed ID: 21482481
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Inhibitors of Mycobacterium tuberculosis PknG Using Pharmacophore Based Virtual Screening, Docking, Molecular Dynamics Simulation, and Their Biological Evaluation.
Singh N; Tiwari S; Srivastava KK; Siddiqi MI
J Chem Inf Model; 2015 Jun; 55(6):1120-9. PubMed ID: 25965448
[TBL] [Abstract][Full Text] [Related]
6. Sclerotiorin inhibits protein kinase G from Mycobacterium tuberculosis and impairs mycobacterial growth in macrophages.
Chen D; Ma S; He L; Yuan P; She Z; Lu Y
Tuberculosis (Edinb); 2017 Mar; 103():37-43. PubMed ID: 28237032
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Leads for antitubercular compounds from kinase inhibitor library screens.
Magnet S; Hartkoorn RC; Székely R; Pató J; Triccas JA; Schneider P; Szántai-Kis C; Orfi L; Chambon M; Banfi D; Bueno M; Turcatti G; Kéri G; Cole ST
Tuberculosis (Edinb); 2010 Nov; 90(6):354-60. PubMed ID: 20934382
[TBL] [Abstract][Full Text] [Related]
9. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
10. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
11. In Silico Identification of Possible Inhibitors for Protein Kinase B (PknB) of
Vieira TF; Martins FG; Moreira JP; Barbosa T; Sousa SF
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684743
[TBL] [Abstract][Full Text] [Related]
12. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
13. Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.
Cavalier JF; Spilling CD; Durand T; Camoin L; Canaan S
Eur J Med Chem; 2021 Jan; 209():112908. PubMed ID: 33071055
[TBL] [Abstract][Full Text] [Related]
14. An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis.
Mori M; Sammartino JC; Costantino L; Gelain A; Meneghetti F; Villa S; Chiarelli LR
Curr Top Med Chem; 2019; 19(9):646-661. PubMed ID: 30827246
[TBL] [Abstract][Full Text] [Related]
15. Antimycobacterial activity of UDP-galactopyranose mutase inhibitors.
Borrelli S; Zandberg WF; Mohan S; Ko M; Martinez-Gutierrez F; Partha SK; Sanders DA; Av-Gay Y; Pinto BM
Int J Antimicrob Agents; 2010 Oct; 36(4):364-8. PubMed ID: 20678902
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Mycobacterial Inhibitors Against Mycobacterial Protein Kinase G.
Kanehiro Y; Tomioka H; Pieters J; Tatano Y; Kim H; Iizasa H; Yoshiyama H
Front Microbiol; 2018; 9():1517. PubMed ID: 30050511
[TBL] [Abstract][Full Text] [Related]
17. Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis.
Li Q; Karim AF; Ding X; Das B; Dobrowolski C; Gibson RM; Quiñones-Mateu ME; Karn J; Rojas RE
Sci Rep; 2016 Jun; 6():27566. PubMed ID: 27297123
[TBL] [Abstract][Full Text] [Related]
18. Lead selection and characterization of antitubercular compounds using the Nested Chemical Library.
Sipos A; Pató J; Székely R; Hartkoorn RC; Kékesi L; Őrfi L; Szántai-Kis C; Mikušová K; Svetlíková Z; Korduláková J; Nagaraja V; Godbole AA; Bush N; Collin F; Maxwell A; Cole ST; Kéri G
Tuberculosis (Edinb); 2015 Jun; 95 Suppl 1():S200-6. PubMed ID: 25801335
[TBL] [Abstract][Full Text] [Related]
19. In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams To Inhibit Mycobacterial Growth.
Wlodarchak N; Teachout N; Beczkiewicz J; Procknow R; Schaenzer AJ; Satyshur K; Pavelka M; Zuercher W; Drewry D; Sauer JD; Striker R
Mol Pharm; 2018 Nov; 15(11):5410-5426. PubMed ID: 30285456
[TBL] [Abstract][Full Text] [Related]
20. Soybean lectin induces autophagy through P2RX7 dependent activation of NF-κB-ROS pathway to kill intracellular mycobacteria.
Mishra A; Behura A; Kumar A; Ghosh A; Naik L; Mawatwal S; Mohanty SS; Mishra A; Saha S; Bhutia SK; Singh R; Dhiman R
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129806. PubMed ID: 33253803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
